|Free Dividend Report|
|Stock Splits Calendar|
|LXRX Stock Split History|
|Preferred Stock Newsletter|
|LXRX Options Chain|
|Stock Message Boards|
Lexicon Pharmaceuticals (LXRX) has 1 split in our LXRX split history database. The split for LXRX took place on May 21, 2015. This was a 1 for 7 reverse split, meaning for each 7 shares of LXRX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 142.857142857143 share position following the split.
When a company such as Lexicon Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the LXRX split history from start to finish, an original position size of 1000 shares would have turned into 142.857142857143 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Lexicon Pharmaceuticals shares, starting with a $10,000 purchase of LXRX, presented on a split-history-adjusted basis factoring in the complete LXRX split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-15.11%|
|About Lexicon Pharmaceuticals|
|Lexicon Pharmaceuticals is a biopharmaceutical company. Co. is commercializing XERMELO® (telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Co. is developing Zynquista (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 2 diabetes. Co. is also developing sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease. Co. is developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. According to our LXRX split history records, Lexicon Pharmaceuticals has had 1 split.|
|LXRX Split History Table|
|05/21/2015||1 for 7|
|Healthcare Stock Splits|
|LXRX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: LXRX shares outstanding history